Biography
Dennis Beringer is an assistant professor in the Center for Translational Immunology (CTI) at the University Medical Center Utrecht, the Netherlands. He obtained his PhD at Utrecht University in the field of structural biology. After which he moved to Monash University, Australia, where he investigated the molecular details of T cell receptor (TCR) – antigen interactions in autoimmune diseases and cancer. Intrigued by TCR biology, he returned to Utrecht to join the group of Jürgen Kuball at the UMCU in 2016 to study the molecular determinants of tumor reactive γδTCRs, for which he received a Marie Curie Individual Fellowship. Currently, he and his team are focusing on the optimization of existing and the development of novel γδ-TCR based therapeutics for cancer therapy, with a special emphasis on a new class of bispecific T cell engagers called GABs.
Research Projects
Bispecific T cell engagers
Protein engineering
Scientific Publications
Top 5:
“Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells.” Hernández-López P, van Diest E, Brazda P, Heijhuurs S, Meringa A, Hoorens van Heyningen L, Riillo C, Schwenzel C, Zintchenko M, Johanna I, Nicolasen MJT, Cleven A, Kluiver TA, Millen R, Zheng J, Karaiskaki F, Straetemans T, Clevers H, de Bree R, Stunnenberg HG, Peng WC, Roodhart J, Minguet S, Sebestyén Z, Beringer DX, Kuball J. Nat Immunol. 2024 Jan;25(1):88-101. doi: 10.1038/s41590-023-01665-0
“The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers.” van Diest E, Nicolasen MJT, Kramer L, Zheng J, Hernández-López P, Beringer DX, Kuball J.
Front Immunol. 2023 Jan 5;13:1052090. doi: 10.3389/fimmu.2022.1052090
“Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds.” van Diest E, Hernández López P, Meringa AD, Vyborova A, Karaiskaki F, Heijhuurs S, Gumathi Bormin J, van Dooremalen S, Nicolasen MJT, Gatti LCDE, Johanna I, Straetemans T, Sebestyén Z, Beringer DX, Kuball J. J Immunother Cancer. 2021 Nov;9(11):e003850. doi: 10.1136/jitc-2021-003850.
“γ9δ2T cell diversity and the receptor interface with tumor cells.” Vyborova A, Beringer DX, Fasci D, Karaiskaki F, van Diest E, Kramer L, de Haas A, Sanders J, Janssen A, Straetemans T, Olive D, Leusen J, Boutin L, Nedellec S, Schwartz SL, Wester MJ, Lidke KA, Scotet E, Lidke DS, Heck AJ, Sebestyen Z, Kuball J. J Clin Invest. 2020 Sep 1;130(9):4637-4651. doi: 10.1172/JCI132489.
“T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex.” Beringer DX, Kleijwegt FS, Wiede F, van der Slik AR, Loh KL, Petersen J, Dudek NL, Duinkerken G, Laban S, Joosten A, Vivian JP, Chen Z, Uldrich AP, Godfrey DI, McCluskey J, Price DA, Radford KJ, Purcell AW, Nikolic T, Reid HH, Tiganis T, Roep BO, Rossjohn J. Nat Immunol. 2015 Nov;16(11):1153-61. doi: 10.1038/ni.3271.